Clinical Trial Detail

NCT ID NCT02572687
Title A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

gastroesophageal junction adenocarcinoma

hepatocellular carcinoma

gastric adenocarcinoma

lung non-small cell carcinoma

Therapies

Durvalumab + Ramucirumab

Age Groups: adult

No variant requirements are available.